OBJECTIVE AND METHODS: Prednisone and its active metabolite prednisolone, both substrates for 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), may represent a pharmacological challenge for the enzyme. The aim of the present work was to define the possible role of abnormal cortisol/cortisone handling, as revealed by an urinary tetrahydrocortisol + allotetrahydrocortisol (THFs)/tetrahydrocortisone (THE) ratio between 1.5 and 3.0, by measuring urinary cortisol and cortisone metabolites in: normotensive individuals (n = 100) who received 7-8 mg/day of oral prednisone and were then followed for development of hypertension; essential hypertensive (EH) participants from primary care (n = 103); and EH hypertensive patients referred to the Hypertension Unit (n = 141). RESULTS: About one-third (14 out of 47, 30%) of glucorticoid-treated patients who developed hypertension showed a THFs/THE ratio >1.5, which was seen in 3% (n = 3) and 14% (n = 19) of primary and tertiary care hypertensive pati...
Urinary cortisol to cortisone metabolites ratio in prednisone-treated and spontaneously hypertensive patients
OLIVIERI, Oliviero;PIZZOLO, Francesca;RAVAGNANI, Viviana;MORETTI, Lorenzo;FACCINI, Giovanni;FRISO, Simonetta;CORROCHER, Roberto
2008-01-01
Abstract
OBJECTIVE AND METHODS: Prednisone and its active metabolite prednisolone, both substrates for 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), may represent a pharmacological challenge for the enzyme. The aim of the present work was to define the possible role of abnormal cortisol/cortisone handling, as revealed by an urinary tetrahydrocortisol + allotetrahydrocortisol (THFs)/tetrahydrocortisone (THE) ratio between 1.5 and 3.0, by measuring urinary cortisol and cortisone metabolites in: normotensive individuals (n = 100) who received 7-8 mg/day of oral prednisone and were then followed for development of hypertension; essential hypertensive (EH) participants from primary care (n = 103); and EH hypertensive patients referred to the Hypertension Unit (n = 141). RESULTS: About one-third (14 out of 47, 30%) of glucorticoid-treated patients who developed hypertension showed a THFs/THE ratio >1.5, which was seen in 3% (n = 3) and 14% (n = 19) of primary and tertiary care hypertensive pati...I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.